Volume 67, Issue 1, Pages (January 2015)

Slides:

Advertisements

Similar presentations

EASL Clinical Practice Guidelines: Vascular diseases of the liver Journal of Hepatology Volume 64, Issue 1, Pages (January 2016) DOI: /j.jhep

Advertisements

Models for the organisation of hospital infection control and prevention programmes B. Gordts Clinical Microbiology and Infection Volume 11, Pages

Early Detection of Prostate Cancer in 2007

Volume 55, Issue 1, Pages 1-8 (January 2009)

Prostate cancer mortality in screen and clinically detected prostate cancer: Estimating the screening benefit Pim J. van Leeuwen, David Connolly, Anna.

The PSA Era is not Over for Prostate Cancer

Volume 50, Issue 1, Pages (July 2006)

Volume 52, Issue 1, Pages (July 2007)

Volume 51, Issue 2, Pages (February 2007)

Volume 64, Issue 3, Pages (September 2013)

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Testosterone Therapy in Men With Prostate Cancer

Global Trends in Testicular Cancer Incidence and Mortality

Volume 61, Issue 6, Pages (June 2012)

Volume 53, Issue 4, Pages (April 2008)

Volume 70, Issue 6, Pages (December 2016)

Volume 61, Issue 5, Pages (May 2012)

Volume 73, Issue 6, Pages (June 2018)

Volume 57, Issue 6, Pages (June 2010)

Diabetic Severity and Risk of Kidney Stone Disease

Prostate Cancer Epidemic in Sight?

Volume 63, Issue 4, Pages (April 2013)

Volume 64, Issue 4, Pages (October 2013)

Volume 64, Issue 4, Pages (October 2013)

Volume 61, Issue 2, Pages (February 2012)

Volume 44, Issue 1, Pages (July 2003)

Volume 59, Issue 6, Pages (June 2011)

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 68, Issue 5, Pages (November 2015)

Measuring the Urologic Iceberg: Design and Implementation of the Boston Area Community Health (BACH) Survey John B. McKinlay, Carol L. Link European.

European Urology Oncology

Ute Ganswindt, Arnulf Stenzl, Michael Bamberg, Claus Belka

Intraductal Carcinoma of the Prostate: Anonymous to Ominous

Prostate Cancer Detection: A View of the Future

Ongoing Gleason Grade Migration in Localized Prostate Cancer and Implications for Use of Active Surveillance Adam B. Weiner, Ruth Etzioni, Scott E. Eggener

Volume 54, Issue 5, Pages (November 2008)

Volume 68, Issue 3, Pages (September 2015)

Next-generation Sequencing of Urologic Cancers: Next Is Now

Low-risk Prostate Cancer: Identification, Management, and Outcomes

Volume 59, Issue 4, Pages (April 2011)

Volume 69, Issue 6, Pages (June 2016)

Volume 69, Issue 3, Pages (March 2016)

Volume 52, Issue 3, Pages (September 2007)

Shaheen Alanee, Kasmintan Schrader, Kenneth Offit European Urology

Volume 66, Issue 6, Pages (December 2014)

Prostate Cancer Epidemic in Sight?

James N. Armitage, Stuart O. Irving, Neil A. Burgess European Urology

The PSA Era is not Over for Prostate Cancer

Global Burden of Urologic Cancers, 1990–2013

The Origin of the Bone Scan as a Tumour Marker in Prostate Cancer

Volume 61, Issue 6, Pages (June 2012)

Volume 53, Issue 4, Pages (April 2008)

Volume 63, Issue 3, Pages (March 2013)

Shifting Paradigms for High-grade Prostatic Intraepithelial Neoplasia

Volume 71, Issue 1, Pages (January 2017)

Volume 64, Issue 4, Pages (October 2013)

Volume 50, Issue 5, Pages (November 2006)

CyberKnife in the Treatment of Prostate Cancer: A Revolutionary System

Volume 55, Issue 3, Pages (March 2009)

Testicular Cancer Variations in Time and Space in Europe

Volume 53, Issue 1, Pages (January 2008)

The 20-Yr Outcome in Patients with Well- or Moderately Differentiated Clinically Localized Prostate Cancer Diagnosed in the Pre-PSA Era: The Prognostic.

European Urology is “Your” Journal

A Multidisciplinary Team Approach for the Optimal Clinical Management of Metastatic Hormone-Refractory Prostate Cancer—Case Study John Fitzpatrick European.

Prostate Cancer Screening Decreases the Absolute Risk of Being Diagnosed with Advanced Prostate Cancer—Results from a Prospective, Population-Based Randomized.

Edith Canby-Hagino, Javier Hernandez, Timothy C. Brand, Ian Thompson

Volume 53, Issue 2, Pages (February 2008)

Volume 51, Issue 2, Pages (February 2007)

Does PSA Testing Influence the Natural History of Prostate Cancer?

Volume 51, Issue 5, Pages (May 2007)

Presentation transcript:

Volume 67, Issue 1, Pages 64-70 (January 2015) Dissecting the Association Between Metabolic Syndrome and Prostate Cancer Risk: Analysis of a Large Clinical Cohort Bimal Bhindi, Jennifer Locke, Shabbir M.H. Alibhai, Girish S. Kulkarni, David S. Margel, Robert J. Hamilton, Antonio Finelli, John Trachtenberg, Alexandre R. Zlotta, Ants Toi, Karen M. Hersey, Andrew Evans, Theodorus H. van der Kwast, Neil E. Fleshner European Urology Volume 67, Issue 1, Pages 64-70 (January 2015) DOI: 10.1016/j.eururo.2014.01.040 Copyright © 2014 European Association of Urology Terms and Conditions

Fig. 1 Biologic gradient that exists between the number of metabolic syndrome components and the odds of prostate cancer (PCa), clinically significant PCa, and intermediate- or high-grade disease. CSPC=clinically significant prostate cancer; I-HGPC=intermediate- or high-grade prostate cancer; ref.=reference value. European Urology 2015 67, 64-70DOI: (10.1016/j.eururo.2014.01.040) Copyright © 2014 European Association of Urology Terms and Conditions